Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer
Sponsor: M.D. Anderson Cancer Center • ClinicalTrials.gov ID: NCT07377006
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
This clinical trial identifies factors associated with completing genetic testing, aids in the development of a decision support tool, and tests how well the decision support tool works to enhance germline genetic testing in patients with prostate cancer. Germline genetic testing is a guideline-recommended standard of care for many patients with prostate cancer. Completing genetic testing can enable the use of targeted therapies, offers access to novel clinical trials, provides valuable information, and can help identify at risk family members. The decision support tool may educate patients and assist in the decision to engage with germline genetic testing.
Interventions
-
Behavioral Intervention
(Behavioral)
View decision support tool
-
Biospecimen Collection
(Procedure)
Undergo blood sample collection
-
Electronic Health Record Review
(Other)
Ancillary studies
-
Genetic Counseling
(Other)
Meet with genetic counselor
-
Genetic Testing
(Other)
Undergo standard of care genetic testing
-
Interview
(Other)
Complete qualitative interview
-
Interview
(Other)
Complete cognitive interview
-
Survey Administration
(Other)
Ancillary studies
Eligibility criteria
Conditions
Locations
- M D Anderson Cancer Center — Houston, Texas, United States
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record